New Vaccine Shows Early Signs Of Stopping Cancer Spread

An experimental cancer vaccine has kept high-risk melanoma from returning for longer and reduced the risk of it spreading in a late-stage trial. Moderna and Merck said Wednesday in a press release that their experimental personalized mRNA vaccine, Intismeran, combined with Merck’s Keytruda, met both its primary and secondary goals in a late-stage trial of ...